Brokerages Expect Zoetis Inc (ZTS) Will Announce Quarterly Sales of $1.41 Billion
Equities analysts expect that Zoetis Inc (NYSE:ZTS) will post $1.41 billion in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Zoetis’ earnings. The lowest sales estimate is $1.39 billion and the highest is $1.42 billion. Zoetis reported sales of $1.28 billion in the same quarter last year, which indicates a positive year over year growth rate of 10.2%. The company is scheduled to report its next quarterly earnings report before the market opens on Thursday, February 15th.
On average, analysts expect that Zoetis will report full-year sales of $1.41 billion for the current year, with estimates ranging from $5.24 billion to $5.27 billion. For the next year, analysts forecast that the firm will post sales of $5.63 billion per share, with estimates ranging from $5.57 billion to $5.69 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Zoetis.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the company posted $0.52 earnings per share. The business’s revenue was up 8.5% on a year-over-year basis.
Zoetis (NYSE ZTS) opened at $75.54 on Wednesday. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. Zoetis has a twelve month low of $52.00 and a twelve month high of $76.40. The stock has a market capitalization of $36,810.00, a PE ratio of 39.76, a P/E/G ratio of 1.90 and a beta of 1.06.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, January 19th will be paid a dividend of $0.126 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 annualized dividend and a dividend yield of 0.67%. Zoetis’s payout ratio is 22.11%.
Several large investors have recently made changes to their positions in ZTS. Franklin Resources Inc. boosted its stake in shares of Zoetis by 7.7% during the 2nd quarter. Franklin Resources Inc. now owns 11,349 shares of the company’s stock worth $708,000 after acquiring an additional 816 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after acquiring an additional 230 shares in the last quarter. Fiera Capital Corp purchased a new stake in shares of Zoetis during the 2nd quarter worth approximately $1,184,000. BT Investment Management Ltd purchased a new stake in shares of Zoetis during the 2nd quarter worth approximately $565,000. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Zoetis by 4.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 188,266 shares of the company’s stock worth $11,745,000 after acquiring an additional 8,528 shares in the last quarter. 93.14% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2018/01/17/brokerages-expect-zoetis-inc-zts-will-announce-quarterly-sales-of-1-41-billion.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related stocks with our FREE daily email newsletter.